Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

181 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Understanding and Overcoming Resistance to Selective FGFR Inhibitors across FGFR2-Driven Malignancies.
Facchinetti F, Loriot Y, Brayé F, Vasseur D, Bahleda R, Bigot L, Barbé R, Nobre C, Combarel D, Michiels S, Italiano A, Smolenschi C, Tselikas L, Scoazec JY, Ponce-Aix S, Besse B, André F, Olaussen KA, Hollebecque A, Friboulet L. Facchinetti F, et al. Among authors: tselikas l. Clin Cancer Res. 2024 Nov 1;30(21):4943-4956. doi: 10.1158/1078-0432.CCR-24-1834. Clin Cancer Res. 2024. PMID: 39226398 Free PMC article.
Focus on Recommendations for the Management of Non-small Cell Lung Cancer.
Lavaud P, Besse B, de Baere T, Deschamps F, Mussot S, Le Pechoux C, Caramella C, Mercier O, Mezquitta L, Botticella A, Pradere P, Adam J, Planchard D, Tselikas L. Lavaud P, et al. Among authors: tselikas l. Cardiovasc Intervent Radiol. 2019 Sep;42(9):1230-1239. doi: 10.1007/s00270-019-02222-9. Epub 2019 May 6. Cardiovasc Intervent Radiol. 2019. PMID: 31062067 No abstract available.
Diverse Resistance Mechanisms to the Third-Generation ALK Inhibitor Lorlatinib in ALK-Rearranged Lung Cancer.
Recondo G, Mezquita L, Facchinetti F, Planchard D, Gazzah A, Bigot L, Rizvi AZ, Frias RL, Thiery JP, Scoazec JY, Sourisseau T, Howarth K, Deas O, Samofalova D, Galissant J, Tesson P, Braye F, Naltet C, Lavaud P, Mahjoubi L, Abou Lovergne A, Vassal G, Bahleda R, Hollebecque A, Nicotra C, Ngo-Camus M, Michiels S, Lacroix L, Richon C, Auger N, De Baere T, Tselikas L, Solary E, Angevin E, Eggermont AM, Andre F, Massard C, Olaussen KA, Soria JC, Besse B, Friboulet L. Recondo G, et al. Among authors: tselikas l. Clin Cancer Res. 2020 Jan 1;26(1):242-255. doi: 10.1158/1078-0432.CCR-19-1104. Epub 2019 Oct 4. Clin Cancer Res. 2020. PMID: 31585938 Free PMC article.
Correction to: Focus on Recommendations for the Management of Non-small Cell Lung Cancer.
Lavaud P, Besse B, de Baere T, Deschamps F, Mussot S, Le Pechoux C, Caramella C, Mercier O, Mezquita L, Botticella A, Pradere P, Adam J, Planchard D, Tselikas L. Lavaud P, et al. Among authors: tselikas l. Cardiovasc Intervent Radiol. 2020 Jan;43(1):168. doi: 10.1007/s00270-019-02370-y. Cardiovasc Intervent Radiol. 2020. PMID: 31690981
Intratumoral Immunotherapy: From Trial Design to Clinical Practice.
Champiat S, Tselikas L, Farhane S, Raoult T, Texier M, Lanoy E, Massard C, Robert C, Ammari S, De Baère T, Marabelle A. Champiat S, et al. Among authors: tselikas l. Clin Cancer Res. 2021 Feb 1;27(3):665-679. doi: 10.1158/1078-0432.CCR-20-0473. Epub 2020 Sep 17. Clin Cancer Res. 2021. PMID: 32943460 Review.
Interventional Radiology for Local Immunotherapy in Oncology.
Tselikas L, Champiat S, Sheth RA, Yevich S, Ammari S, Deschamps F, Farhane S, Roux C, Susini S, Mouraud S, Delpla A, Raoult T, Robert C, Massard C, Barlesi F, Soria JC, Marabelle A, de Baere T. Tselikas L, et al. Clin Cancer Res. 2021 May 15;27(10):2698-2705. doi: 10.1158/1078-0432.CCR-19-4073. Epub 2021 Jan 8. Clin Cancer Res. 2021. PMID: 33419781 Review.
Long Term Efficacy and Assessment of Tumor Response of Transarterial Chemoembolization in Neuroendocrine Liver Metastases: A 15-Year Monocentric Experience.
Touloupas C, Faron M, Hadoux J, Deschamps F, Roux C, Ronot M, Yevich S, Joskin J, Gelli M, Barbé R, Lamartina L, Tissot H, Scoazec JY, Malka D, Ducreux M, Baudin E, de Baère T, Tselikas L. Touloupas C, et al. Among authors: tselikas l. Cancers (Basel). 2021 Oct 26;13(21):5366. doi: 10.3390/cancers13215366. Cancers (Basel). 2021. PMID: 34771531 Free PMC article.
Synergizing liver systemic treatments with interventional oncology: friend or foe?
Jost R, Al-Shatti N, Ghosn M, Bonnet B, Champiat S, Deschamps F, Gelli M, Boige V, Danlos FX, Susini S, Hollebecque A, Ammari S, Marabelle A, de Baere T, Tselikas L. Jost R, et al. Among authors: tselikas l. Br J Radiol. 2022 Sep 1;95(1138):20220548. doi: 10.1259/bjr.20220548. Epub 2022 Sep 8. Br J Radiol. 2022. PMID: 36075034 Free PMC article. Review.
Immunotherapy and Hepatocellular Cancer: Where Are We Now?
Valery M, Cervantes B, Samaha R, Gelli M, Smolenschi C, Fuerea A, Tselikas L, Klotz-Prieux C, Hollebecque A, Boige V, Ducreux M. Valery M, et al. Among authors: tselikas l. Cancers (Basel). 2022 Sep 19;14(18):4523. doi: 10.3390/cancers14184523. Cancers (Basel). 2022. PMID: 36139683 Free PMC article. Review.
Genomic Instability and Protumoral Inflammation Are Associated with Primary Resistance to Anti-PD-1 + Antiangiogenesis in Malignant Pleural Mesothelioma.
Danlos FX, Texier M, Job B, Mouraud S, Cassard L, Baldini C, Varga A, Yurchenko AA, Rabeau A, Champiat S, Letourneur D, Bredel D, Susini S, Blum Y, Parpaleix A, Parlavecchio C, Tselikas L, Fahrner JE, Goubet AG, Rouanne M, Rafie S, Abbassi A, Kasraoui I, Breckler M, Farhane S, Ammari S, Laghouati S, Gazzah A, Lacroix L, Besse B, Droin N, Deloger M, Cotteret S, Adam J, Zitvogel L, Nikolaev SI, Chaput N, Massard C, Soria JC, Gomez-Roca C, Zalcman G, Planchard D, Marabelle A. Danlos FX, et al. Among authors: tselikas l. Cancer Discov. 2023 Apr 3;13(4):858-879. doi: 10.1158/2159-8290.CD-22-0886. Cancer Discov. 2023. PMID: 36669143 Free PMC article.
181 results